Luiza Ianny De Lima

Luiza Ianny De Lima

Auto-generated profile, based on publicly available information

Luiza Ianny De Lima

University of Brasilia

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2020 in Journal of Health & Biological Sciences
Verified
Journal Article
Open access
PDF file
Thyago José Arruda PachecoThyago José Arruda Pacheco
Thyago José Arruda Pacheco
Danielle Galdino De SouzaDanielle Galdino De Souza
Danielle Galdino De Souza
LLLuiza Ianny De Lima
Luiza Ianny De Lima
João Paulo Figueiró LongoJoão Paulo Figueiró Longo
João Paulo Figueiró Longo
Objetivo: analisar os recentes estudos com a hidroxicloroquina no tratamento da COVID-19. Métodos: comunicação breve relatando os principais resultados com o uso da hidroxicloroquina em ensaios clínicos e o panorama mundial desses estudos. Resultados: a maioria dos ensaios clínicos no mundo é com a hidroxicloroquina, e os resultados com o seu uso são variados. Conclusão: é urgente avaliar melhor a eficácia da hidroxicloroquina no possível tratamento da COVID-19 em pacientes não severos.

28 March 2021 in Research, Society and Development
Verified
Journal Article
Open access
PDF file
RFRaquel Santos Faria
Raquel Santos Faria
Danielle Galdino De SouzaDanielle Galdino De Souza
Danielle Galdino De Souza
Thyago José Arruda PachecoThyago José Arruda Pacheco
Thyago José Arruda Pacheco
FSFranciéle MATOS Silva
Franciéle MATOS Silva
VMVictor Mello
Victor Mello
LLLuiza Ianny de Lima
Luiza Ianny de Lima
Optimizing drug combination treatment has been an area of interest for a while, from the beginning with the emergence of the POMP regime. The ability to improve drug combinations for cancer treatment comes up against the possibility of several limitations, such as the lack of specificity of the drugs, generating systemic toxic effects, and also the great possibility of generating tumor cells resistant to the drugs. The development of nanooncology offers advances in new alternatives for the treatment of cancer, especially breast cancer. The strategy of using drugs combined in a nanocarrier for the treatment of breast cancer has proven to be quite effective, taking into account that breast cancer has long shown a good response with therapeutic combinations. In this work, we present a review of some examples of nanoformulations developed with the combination of drugs doxorubicin and/or paclitaxel aimed for the treatment of breast cancer. Also the future perspectives of nanotechnology in the drug combination.